Drugs /

bcl201

Back to Drugs List

Overview

NCI Definition [1]:
A selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2 inhibitor BCL201 binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.

Clinical Trials

View Clinical Trials for bcl201

Bcl201 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating bcl201, 1 is phase 1 (0 open).

IGH-CCND1 Fusion and t(11;14)(q13;q32) are the most frequent biomarker inclusion criteria for bcl201 clinical trials.

Chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma are the most common diseases being investigated in bcl201 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Bcl201
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating bcl201 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
servier-1, bcl-201, bcl-2 inhibitor bcl201, s55746, servier 1, s-55746, bcl-2 inhibitor bcl201
Drug Target(s) [2]:
BCL2
NCIT ID [1]:
C125603

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.